Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy
J Li, L Huang, H Zhou, Y Shan, F Chen… - Acta Pharmacologica …, 2022 - nature.com
Immunotherapy, in particular immune checkpoint blockade (ICB) therapy targeting the
programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis, has …
programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis, has …
Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy
S Liu, H Wang, X Shao, H Chen, S Chao… - Journal of …, 2023 - Springer
In recent years, cancer immunotherapy has emerged as an exciting cancer treatment.
Immune checkpoint blockade brings new opportunities for more researchers and clinicians …
Immune checkpoint blockade brings new opportunities for more researchers and clinicians …
How to treat melanoma? the current status of innovative nanotechnological strategies and the role of minimally invasive approaches like PTT and PDT
Melanoma is the most aggressive type of skin cancer, the incidence and mortality of which
are increasing worldwide. Its extensive degree of heterogeneity has limited its response to …
are increasing worldwide. Its extensive degree of heterogeneity has limited its response to …
Nanodrugs targeting T cells in tumor therapy
M Haist, V Mailänder, M Bros - Frontiers in Immunology, 2022 - frontiersin.org
In contrast to conventional anti-tumor agents, nano-carriers allow co-delivery of distinct
drugs in a cell type-specific manner. So far, many nanodrug-based immunotherapeutic …
drugs in a cell type-specific manner. So far, many nanodrug-based immunotherapeutic …
Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model
Abstract Combretastatin A4 (CA4), a vascular disrupting agent has been recently proposed
as an anticancer agent. However, its low water solubility and low bioavailability limited its …
as an anticancer agent. However, its low water solubility and low bioavailability limited its …
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
GL Ma, WF Lin - Military Medical Research, 2023 - Springer
Immune checkpoint blockade (ICB) therapy for cancer has achieved great success both in
clinical results and on the market. At the same time, success drives more attention from …
clinical results and on the market. At the same time, success drives more attention from …
[HTML][HTML] Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Cancer immunotherapy represents a revolutionary strategy, leveraging the patient's immune
system to inhibit tumor growth and alleviate the immunosuppressive effects of the tumor …
system to inhibit tumor growth and alleviate the immunosuppressive effects of the tumor …
A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors
RA Paun, S Jurchuk, M Tabrizian - … & Translational Medicine, 2024 - Wiley Online Library
Lipid nanoparticles (LNPs) are biocompatible drug delivery systems that have found
numerous applications in medicine. Their versatile nature enables the encapsulation and …
numerous applications in medicine. Their versatile nature enables the encapsulation and …
[HTML][HTML] Emerging Progress of RNA-Based Antitumor Therapeutics
J Fu, H Dong, J Wu, Y Jin - International Journal of Biological …, 2023 - ncbi.nlm.nih.gov
RNA-based therapeutics (eg, mRNAs, siRNAs, microRNAs, ASOs, and saRNAs) have
considerable potential for tumor treatment. The development and optimization of RNA …
considerable potential for tumor treatment. The development and optimization of RNA …
A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells
Objectives Programmed cell death 1 (PD-1) is a member of the CD28/CTLA-4 family of
inhibitory immunological checkpoint receptors that's also widely produced by exhausted T …
inhibitory immunological checkpoint receptors that's also widely produced by exhausted T …